Evaluate the Efficacy of the OITcontrol Application.

Exclusion Criteria

• •1. Allergy to cow's milk and/or eggs not mediated by IgE.
• •2. Uncontrolled asthma. In the case of a patient with asthma, this must be controlled before the start of OIT.
• •3. Severe atopic dermatitis.
• •4. Previous diagnosis of eosinophilic esogaphitis.
• •5. Inflammatory bowel disease.
• •6. Mastocytosis.
• •7. Immunocompromised patients.
• •8. Disorders and/or treatments in which the use of adrenaline is contraindicated.
• •9. Difficulty understanding the risks and benefits of the procedure, and social and family factors that may compromise long-term maintenance therapy. This includes conflicts between parents or legal representatives that may adversely affect treatment.
• •10. Inability of parents or legal representative to follow instructions, identify reactions, or administer medication (especially auto-injectable adrenaline).
• •Previous allergic reaction with the corresponding OIT food within the month prior to the initial visit.
• •Treatment with omalizumab or any other immunomodulatory biologic drug within the three months prior to the initial visit.
• •Pregnant women, or women of childbearing potential not using a safe means of contraception (abstinence is considered an acceptable method) during the entire study period.